Dan Ledger

Senior Research Scientist @CrystecPharma interested in the latest #supercritical fluid, #crystallography, #engineering and #pharma research

[CrystecPharma Ltd @CrystecPharma]

Ritonavir (an HIV drug) is a classic example of how polymorphism plays a huge role in the drug development process. Have a read to find out how Crystec can help with any polymorph issues you may be facing: https://t.co/JLDd53jvML

#crystallography #polymorphism #drugdevelopment

[CrystecPharma Ltd @CrystecPharma]

We’re back in beautiful Edinburgh for Drug Delivery to the Lungs (DDL) 2022 this week! After a great morning, we’re looking forward to seeing more familiar faces, and exploring the exhibition hall. Let us know if you’re here too.

#edinburgh #DDL2022 #DDL #drugdevelopment

[CrystecPharma Ltd @CrystecPharma]

Crystec are honoured to be working with SignalRx and ADYA on a novel inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis (#IPF). This animation, is a great explainer describing the symptoms of, and treatments for, IPF https://t.co/haPoZaBtsY.
#ddl #lungdisease

[CrystecPharma Ltd @CrystecPharma]

Crystec’s mSAS® technology platform is perfectly placed to accelerate the development of inhaled therapeutics. As a single-step alternative to micronisation, we can generate a concept product within an 8 week feasibility study. Check out this video https://t.co/LwYB5hZH3i!

[CrystecPharma Ltd @CrystecPharma]

As we come to the end of COPD Awareness month, have a read of what Crystec have been doing to help with glycopyrronium bromide, a drug that is currently used as monotherapy, and in combination, for the maintenance treatment of COPD.

https://t.co/x42QlHnyhV

[CrystecPharma Ltd @CrystecPharma]

We’re continuing to support COPD Awareness month this week. Have a read of how Crystec can help in the rapid development of combination COPD products:

https://t.co/o8ShkIHkZe

[CrystecPharma Ltd @CrystecPharma]

Our Business Development Director, Catherine Hunter, will be at @DDLConferences in Edinburgh next month. Get in touch with her today to arrange a meeting to discuss recent advances with our inhaled development services ([email protected]). See you all soon! #ddl

[CrystecPharma Ltd @CrystecPharma]

Our Chief Scientist, Professor Peter York, was recently invited to lead contributions to a thought leadership article "Putting a Spotlight on Particle Engineering." You can find the full article here:
https://t.co/Uv4dsI0eSX.
#lifesciences #pharmaceutical #msas #drugdelivery

[CrystecPharma Ltd @CrystecPharma]

November is COPD awareness month!

COPD is the third leading cause of death worldwide, affecting 16 million adults, with another 16 million or more remaining undiagnosed.

Have a read to see what Crystec are doing to help:
https://t.co/bVi6NeOd3S

[CrystecPharma Ltd @CrystecPharma]

Today is World COPD Day 2022! There still remains a significant level of unmet clinical need and a requirement for improved products.

Have a read of our post to see what Crystec are doing to help reduce the burden of COPD worldwide: https://t.co/Ecl8WL9bIR

[CrystecPharma Ltd @CrystecPharma]

As we start another week, this is your reminder to book a meeting with our experts at @CPHI_Events 2022! The event kicks off a week tomorrow and we would love to see you there. To book a discussion, contact us today at [email protected].
#cphi2022 #msas #cphifrankfurt

[CrystecPharma Ltd @CrystecPharma]

The second category that we have been shortlisted in for the @CPHI_Events Awards is ‘Finished Formulation’.
CrystecPharma’s in-particle design® services have recently expanded, bringing a pioneering approach to formulation development. Want to know more? [email protected]

[CrystecPharma Ltd @CrystecPharma]

Crystec are delighted to have been shortlisted as a
@CPHI_Events Excellence in Pharma Awards Finalist for the second year running – this time in two categories!
We will talk in more detail about each category over the next couple of days so keep your eyes peeled!

[CrystecPharma Ltd @CrystecPharma]

Never stop searching! After a tumultuous journey so far, a new form of #ritonavir has been identified....after 24 years! Crystal formation is truly amazing. https://t.co/fzteuZfoiQ
https://t.co/SIEvIPbGDd).

[CrystecPharma Ltd @CrystecPharma]

We have been broadening the use of mSAS® technology to accelerate the development of inhaled products, including development of a specific novel, DPI treatment for COPD.

Check out our post for more information about what drugs we have been working on:

https://t.co/6OCh8FvHMK

[CrystecPharma Ltd @CrystecPharma]

Have you seen our video demonstrating the ease with which particles generated by Crystec’s mSAS® technology aerosolise compared with a micronised equivalent? https://t.co/jiWk0wqjRF
Find out more at https://t.co/eUEfupCCbZ
#inhalation #pharma #drugdelivery

[CrystecPharma Ltd @CrystecPharma]

Here is a fun visualisation of what a supercritical fluid is!
https://t.co/UOlMuCnH82

Crystec uses a supercritical fluid (SCF) anti-solvent ‘bottom-up’ #particle #engineering process (mSAS®) to take advantage of the solvating power of SCF.

[CrystecPharma Ltd @CrystecPharma]

At CrystecPharma we believe that a directed modified supercritical anti-solvent (mSAS) screen gives us the best chance of finding new polymorphs predicted by Crystal Structure Prediction software.
https://t.co/q1TjHEJbIQ

#pharmaceuticalmanufacturing #crystallization #polymorphs

[CrystecPharma Ltd @CrystecPharma]

Twitter Did you know that mSAS® offers a range of strategies to overcome poor drug solubility? Watch our video to find out more!
https://t.co/jwCDCAAHZG
For further information, check out our blogpost at https://t.co/te9vECeDvl
#drugdelivery #drugsolubility

[CrystecPharma Ltd @CrystecPharma]

Processing proteins into stable powders has many challenges. Have a read of our blog post https://t.co/M0bhHDIeAa to see how we, at CrystecPharma, generate temperature stable biotherapeutics with high levels of retained activity, capable of being readily reconstituted.